[RESEARCH BLOG] · 2026-07-21

NewAmsterdam Pharma (NAMS) – Sell Signal Amid Crisis‑Mode Market Regime and Deep‑Rooted Financial Distress

By Pierre Brunelle · Founder & Research Lead

NAMSSELLCRISISsell flip

Lede: NewAmsterdam Pharma N.V. closed at $29.67, a 6.34 % decline from the prior session, as of 2026‑07‑20. The LOPJLB proprietary scanner now flags the stock with a SELL directional signal, a CRISIS market regime, and a composite score of ‑5.

Fundamentals and Valuation

NewAmsterdam Pharma’s balance sheet and income statement paint a picture of a company still wrestling with the economics of late‑stage drug development. The trailing twelve‑month (TTM) price‑to‑earnings (P/E) ratio sits at –16.39, indicating that earnings are negative and that the market is pricing the stock on forward expectations rather than current profitability. The enterprise‑value‑to‑EBITDA (EV/EBITDA) ratio is –14.17, reinforcing the notion that operating cash flow remains in the red.

Margins are extreme outliers for a biotech firm. While the gross margin is reported at 97.52 %, reflecting the low cost of goods for a small‑molecule pipeline, the operating margin plunges to ‑953.6 % and the net margin to ‑942.8 %. These figures illustrate that research, development, and administrative expenses dwarf any revenue generated. The free‑cash‑flow (FCF) yield is –4.10 %, confirming that the company is a net cash consumer.

Return metrics are equally stark. Return on invested capital (ROIC) is ‑17.88 %, while return on equity (ROE) and return on assets (ROA) sit at ‑29.49 % and ‑29.04 %, respectively. Such negative returns signal that shareholders’ capital is being eroded rather than enhanced.

Revenue growth has been volatile. The latest snapshot shows a ‑52.13 % year‑over‑year revenue decline, a continuation of a pattern that began in 2022 when revenue fell from $102.7 million to $14.1 million in 2023, rebounded to $45.6 million in 2024, and slipped again to $22.5 million in 2025. The earnings per share (EPS) trajectory mirrors this turbulence, moving from ‑$1.15 in 2020 to ‑$2.56 in 2024, before a modest improvement to ‑$1.75 in 2025.

Despite the bleak fundamentals, analysts remain optimistic. The consensus target price is $49.75, and the prevailing recommendation is a Buy. This divergence between market pricing (current $29.67) and analyst expectations underscores the speculative nature of the stock, driven largely by the potential upside of the Obicetrapib program.

Metric	Value
P/E (TTM)	–16.39
EV/EBITDA	–14.17
Gross Margin	97.52 %
Operating Margin	–953.6 %
Net Margin	–942.8 %
ROIC	–17.88 %
Analyst Target	$49.75
Market Cap	$3.47 B

The valuation snapshot highlights a stark disconnect: a price‑to‑book (P/B) ratio of 5.40 suggests that the market is valuing the company well above its net asset base, while the % of discounted cash‑flow (DCF) at 837.3 % indicates that DCF models are heavily discounting future cash flows, reflecting high uncertainty.

ETF Ownership

NewAmsterdam Pharma is held by a narrow set of exchange‑traded funds, concentrating ownership among a few institutional investors. The two largest ETF holders are DRKY (the Direxion Daily Healthcare Bull 3X Shares) with a 4.20 % stake, ranking ninth among the fund’s holdings, and SBIO (the Sprott BioShares Short ETF) with a 2.10 % position, ranking thirteenth.

ETF	Weight
DRKY	4.20 %
SBIO	2.10 %

Such concentrated exposure can amplify price movements when the ETFs rebalance, especially in a crisis‑mode market regime where liquidity is thin. While the presence of a leveraged healthcare bull ETF (DRKY) may provide a modest floor of demand, the short‑focused SBIO position could exert downward pressure if the fund intensifies its short exposure. Investors should be aware that ETF flows can add a layer of volatility beyond the company’s intrinsic fundamentals.

Market Pulse and Regime Context

The LOPJLB signal engine places NAMS in a CRISIS market regime, a classification triggered after four consecutive days of heightened downside pressure. The broader market pulse, however, remains BULL for the past fourteen days, with a breadth metric indicating 47 % of stocks in a buying stance. This divergence suggests that while the overall market sentiment is positive, NAMS is experiencing isolated stress, likely driven by its deteriorating financial metrics and the recent price drop of 6.34 %.

Technical breadth signals from the scanner note a flat positioning, with the underlying reason being an EMA bearish crossover (the 5‑day EMA falling below the 20‑day EMA). The crossover gap of ‑0.0065 and negative velocity measures (‑0.0113 net breadth) reinforce the short‑term downside bias. Although the macro calendar lists a modest consumer confidence change in Australia on 2026‑07‑14, there is no direct linkage to NAMS’s performance, but the broader macro environment remains a backdrop to the company’s challenges.

LOPJLB Signal Read

The LOPJLB platform currently flags NAMS with a SELL directional signal, set against a CRISIS market regime. The composite PERF score of 18.40 and a FUND quality score of 0.00 reflect a blend of weak performance momentum and minimal quality cushion. The stock’s Value score of 2.00, Growth score of 21.00, GARP score of 5.60, and Quality score of 31.40 combine to produce a Balanced archetype, indicating that the model does not lean heavily toward pure value or pure growth.

Investors interested in the full overlay of technical and quantitative signals can explore the interactive chart on the LOPJLB stock page, and review the detailed methodology at the LOPJLB methodology hub.

Closing Remarks

NewAmsterdam Pharma remains a high‑risk, high‑potential play in the cardiometabolic space, anchored by its oral CETP inhibitor Obicetrapib. However, the convergence of a negative earnings profile, deeply negative margins, volatile revenue trends, and a SELL signal in a CRISIS regime creates a challenging investment landscape.

For a deeper dive into the data, charts, and model assumptions, visit the dedicated stock page at https://www.lopjlb.com/stock/NAMS. If the earnings‑call transcript becomes available, the supplemental analysis can be found at https://www.lopjlb.com/stock/NAMS/earnings.md. To explore other opportunities filtered by similar signal criteria, use the LOPJLB screener.

The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consider their risk tolerance before making any trading decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

Open NAMS signal detail → · Open screener → · Methodology